The therapeutic promise of RNA depends on effective delivery, with lipid nanoparticles (LNPs) serving as the most widely used vehicle. However, incomplete characterization of LNP properties and limited understanding of their biological activity can undermine both drug efficacy and safety. In this webinar, Matt Westfall, Mike Heaven, and Adam Aulbach will present an integrated approach to LNP-based RNA drug development, combining detailed LNP profiling, multiomics analysis, and in vivo validation to help scientists advance candidates more precisely and efficiently.
Topics to be covered:
- Essential techniques for LNP characterization to ensure quality and consistency
- An integrated workflow for LNP-based drug development from initial characterization to in vivo validation
- Multiomics insights and design factors that help optimize LNP efficacy, safety, and targeting
Thursday, July 17th, 2025 | 11:00 AM - 12:30 PM Eastern Time
Speakers
Matt Westfall, PhD
Senior Director of Research and Development, Proteomics
Inotiv
Mike Heaven, PhD
Principal Scientist, Bioanalytical Operations
Inotiv
Adam Aulbach, DVM, DABT, DACVP
Vice President, Pathology
Inotiv
